These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 3545448

  • 1. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J, Caggana M, Beck KA.
    Cancer Res; 1987 Mar 15; 47(6):1598-601. PubMed ID: 3545448
    [Abstract] [Full Text] [Related]

  • 2. Potential intracellular target proteins of the anticarcinogenic Bowman Birk protease inhibitor identified by affinity chromatography.
    Billings PC, St Clair W, Owen AJ, Kennedy AR.
    Cancer Res; 1988 Apr 01; 48(7):1798-802. PubMed ID: 3280120
    [Abstract] [Full Text] [Related]

  • 3. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor.
    Billings PC, Habres JM, Liao DC, Tuttle SW.
    Cancer Res; 1991 Oct 15; 51(20):5539-43. PubMed ID: 1913672
    [Abstract] [Full Text] [Related]

  • 4. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
    Chen YW, Huang SC, Lin-Shiau SY, Lin JK.
    Carcinogenesis; 2005 Jul 15; 26(7):1296-306. PubMed ID: 15746161
    [Abstract] [Full Text] [Related]

  • 5. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
    Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR.
    Arch Biochem Biophys; 1997 Aug 01; 344(1):133-8. PubMed ID: 9244390
    [Abstract] [Full Text] [Related]

  • 6. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
    Malkowicz SB, Liu SP, Broderick GA, Wein AJ, Kennedy AR, Levin RM.
    Neurourol Urodyn; 2003 Aug 01; 22(1):54-7. PubMed ID: 12478602
    [Abstract] [Full Text] [Related]

  • 7. Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor.
    St Clair WH.
    Carcinogenesis; 1991 May 01; 12(5):935-7. PubMed ID: 2029760
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of oral carcinogenesis by a protease inhibitor.
    Messadi DV, Billings P, Shklar G, Kennedy AR.
    J Natl Cancer Inst; 1986 Mar 01; 76(3):447-52. PubMed ID: 3081747
    [Abstract] [Full Text] [Related]

  • 9. Complete amino acid sequence of the lentil trypsin-chymotrypsin inhibitor LCI-1.7 and a discussion of atypical binding sites of Bowman-Birk inhibitors.
    Weder JK, Hinkers SC.
    J Agric Food Chem; 2004 Jun 30; 52(13):4219-26. PubMed ID: 15212472
    [Abstract] [Full Text] [Related]

  • 10. In vitro inhibition of the activation of Pro-matrix Metalloproteinase 1 (Pro-MMP-1) and Pro-matrix metalloproteinase 9 (Pro-MMP-9) by rice and soybean Bowman-Birk inhibitors.
    Bawadi HA, Antunes TM, Shih F, Losso JN.
    J Agric Food Chem; 2004 Jul 28; 52(15):4730-6. PubMed ID: 15264907
    [Abstract] [Full Text] [Related]

  • 11. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro.
    Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR.
    Proc Natl Acad Sci U S A; 1985 Aug 28; 82(16):5395-9. PubMed ID: 3860869
    [Abstract] [Full Text] [Related]

  • 12. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells.
    Ware JH, Wan XS, Kennedy AR.
    Nutr Cancer; 1999 Aug 28; 33(2):174-7. PubMed ID: 10368813
    [Abstract] [Full Text] [Related]

  • 13. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells.
    Zhang L, Wan XS, Donahue JJ, Ware JH, Kennedy AR.
    Nutr Cancer; 1999 Aug 28; 33(2):165-73. PubMed ID: 10368812
    [Abstract] [Full Text] [Related]

  • 14. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR, Szuhaj BF, Newberne PM, Billings PC.
    Nutr Cancer; 1993 Aug 28; 19(3):281-302. PubMed ID: 8346077
    [Abstract] [Full Text] [Related]

  • 15. Antiapoptotic activity of the Bowman-Birk inhibitor can be attributed to copurified phospholipids.
    Foehr MW, Tomei LD, Goddard JG, Pemberton PA, Bathurst IC.
    Nutr Cancer; 1999 Aug 28; 34(2):199-205. PubMed ID: 10578488
    [Abstract] [Full Text] [Related]

  • 16. Identification of a soluble enzyme from C3H/10T1/2 cells which is inhibited by the Bowman-Birk proteinase inhibitor.
    Fagan JM, Waxman L.
    Biochem Biophys Res Commun; 1991 Aug 15; 178(3):856-61. PubMed ID: 1872865
    [Abstract] [Full Text] [Related]

  • 17. Proteinase inhibition using small Bowman-Birk-type structures.
    Fernandez JH, Mello MO, Galgaro L, Tanaka AS, Silva-Filho MC, Neshich G.
    Genet Mol Res; 2007 Oct 05; 6(4):846-58. PubMed ID: 18058707
    [Abstract] [Full Text] [Related]

  • 18. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR.
    Int J Radiat Biol; 2023 Oct 05; 99(6):882-890. PubMed ID: 34325613
    [Abstract] [Full Text] [Related]

  • 19. Prevention of carcinogenesis by protease inhibitors.
    Kennedy AR.
    Cancer Res; 1994 Apr 01; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
    [Abstract] [Full Text] [Related]

  • 20. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans.
    Birk Y.
    Int J Pept Protein Res; 1985 Feb 01; 25(2):113-31. PubMed ID: 3886572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.